Sanam Pangali
About Sanam Pangali
Sanam Pangali serves as Chief Legal Officer and Corporate Secretary of Alumis, promoted from Senior Vice President, Legal in July–August 2025; she brings nearly two decades of legal experience across biopharma, technology, and renewable energy industries . During Q2 2025, Alumis reported cash and marketable securities of $486.3M, collaboration revenue of $2.7M, and net income of $59.3M driven by a $187.9M non-operating gain associated with the ACELYRIN merger, providing a strong capital base for pipeline execution .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Alumis Inc. | Senior Vice President, Legal | Through July 2025 | Member of senior leadership; promoted to Chief Legal Officer and Corporate Secretary |
Fixed Compensation
- Not disclosed for Ms. Pangali in the latest proxy; Alumis’ named executive officer cash elements are provided for other executives but do not include Ms. Pangali .
Performance Compensation
Stock option awards and vesting schedules:
| Grant Type | Grant Date | Shares | Exercise Price | Expiration | Vesting Schedule |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 10/09/2024 | 152,400 | $10.29 | 10/09/2034 | 25% on 09/30/2025, remainder in equal monthly installments over 36 months; subject to acceleration and Continuous Service |
| Stock Option (Right to Buy) | 02/17/2025 | 41,000 | $5.06 | 02/17/2035 | 25% on 02/18/2026, remainder in equal monthly installments over 36 months; subject to acceleration and Continuous Service |
Equity Ownership & Alignment
| Category | Detail |
|---|---|
| Direct share ownership | 1,111 common shares, Direct (D) |
| Derivative holdings | Options covering 152,400 shares @ $10.29 expiring 10/09/2034; 41,000 shares @ $5.06 expiring 02/17/2035 |
| Insider trading policy | Alumis prohibits pledging, hedging, public options trading in company securities, and holding stock in margin accounts; designed to enforce alignment and limit hedging/pledging risk |
| Clawback policy | Compensation recovery policy adopted June 2024 per Dodd-Frank, Nasdaq, and SEC rules |
Employment Terms
Alumis Severance and Change in Control Plan (company-wide framework; individual participation requires a signed participation agreement):
| Scenario | Cash Severance | Bonus Treatment | Benefits | Equity Treatment |
|---|---|---|---|---|
| Within Change-in-Control (CIC) Period (12 months post-CIC) | 6–18 months of base salary, tier-based | 1.00x–1.50x target bonus (tier-based; pro-rated if applicable) | Company-paid COBRA during severance period (subject to earlier of COBRA eligibility expiration or new coverage) | Full acceleration of outstanding, unvested equity awards |
| Outside CIC Period | 3–12 months of base salary, tier-based | Pro-rated target bonus for year of termination | Company-paid COBRA during severance period | Acceleration available for certain outstanding unvested equity granted before plan adoption |
| Conditions | Requires execution of separation agreement with general release; includes confidentiality and non-compete restrictions no broader than the standard Confidentiality Agreement | |||
| Forfeiture | Benefits can be terminated or clawed back for prohibited actions (e.g., breach of confidentiality/non-solicit/non-compete or non-disparagement), or failure to comply with plan terms |
Note: Eligibility and exact multiples depend on tier designation in the individual Participation Agreement under the plan .
Performance & Track Record
Company operating context during Ms. Pangali’s tenure:
| Metric | Q2 2025 |
|---|---|
| Cash, cash equivalents, and marketable securities | $486.3M |
| Collaboration revenue | $2.7M |
| R&D expense | $108.8M |
| G&A expense | $34.5M |
| Net income | $59.3M (includes $187.9M non-operating gain from ACELYRIN merger) |
Corporate changes and governance:
- Alumis completed its merger with ACELYRIN on May 21, 2025; net share exchange ratio was 0.4814 Alumis shares per ACELYRIN share .
- Ms. Pangali was promoted to Chief Legal Officer and Corporate Secretary; previously SVP Legal .
Compensation Committee Analysis
- Composition (June 2025): Alan Colowick (Chair), James Tananbaum, Lynn Tetrault; all independent under Nasdaq rules .
- Responsibilities: CEO and executive pay approval, administration of equity/incentive plans, severance/change-in-control protections, succession planning, and compensation strategy oversight .
- Board independence and governance: Majority independent; committee charters and governance guidelines in place .
Investment Implications
- Alignment: Monthly vesting over 36 months across two option grants aligns long-term service with equity ownership; company-wide prohibition on pledging and hedging reduces misalignment risk .
- Change-in-control economics: The Severance Plan’s full equity acceleration and cash severance (salary plus target bonus multiples) in the CIC period can increase realized compensation in strategic transactions; retention protections outside CIC balance continuity and risk mitigation .
- Disclosure gaps: Fixed cash compensation and specific performance bonus metrics for Ms. Pangali are not disclosed in the proxy; ongoing monitoring of future proxies and 8-Ks is needed to assess pay-for-performance calibration .